Both preclinical and clinical data suggest that combined inhibition of autophagy plus specific signaling pathways such as the RAF > MEK > ERK MAP kinase pathway may become a novel and effective treatment strategy for certain cancers driven by BRAFV600E, and may potentially be efficacious for a broader group of KRAS-driven cancers. Here, KRAS is linked to cancer.